ClinicalTrials.gg
Not yet recruitingNCT07680101Updated Jul 2, 2026

Intra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration.

An interventional study of Adelmidrol 2% / Hyaluronic Acid 1% and micronized Palmitoylethanolamide (mPEA) 300mg + ultramicronized Palmitoylethanolamide (umPEA) 600mg in Degenerative Joint Disease of Knee and Rheumatoid Arthritis, sponsored by Universita di Verona. Not yet recruiting at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 106 studies in Osteoarthritis, Knee with a site in Italy — 29 open to participants now, 33 under way, 3 of them phase 3. Osteoarthritis, Knee · Italy.

Planned enrollment
36th of 84
80 · median 65
Started
2026
with 3 others
No phase
59 of 106
18 open now
Primary completion
2027-06
later than 23 of 32 live
Registered
106th of 106
by date

Among the 106 studies in Osteoarthritis, Knee with a site in Italy, this one is the 36th largest by planned enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2026, is one of 59 with no phase, reaches primary completion later than 23 of the 32 other live ones, and was the 106th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

29 of the 106 studies in Osteoarthritis, Knee with a site in Italy are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoarthritis, Knee with a site in Italy, or all of them as a file.
02

Study summary

Degenerative knee joint diseases are characterized by chronic pain, inflammation, and functional impairment. In these conditions, mast cell density in the synovial membrane is increased, resulting in an excessive release of biological mediators involved in key mechanisms of neuroinflammation and in hyaluronic acid depolymerisation. Adelmidrol acts as a preventive antioxidant due to its radical scavenging activity, thus protecting hyaluronic acid from oxidative degradation and reducing mast cell degranulation. Furthermore, a reduction in endogenous Palmitoylethanolamide (PEA) levels also contributes to joint neuroinflammation and disease progression; therefore, its exogenous supplementation may represent a valuable supportive strategy.

The objective of this clinical investigation is to compare the efficacy of intra-articular adelmidrol/hyaluronic acid treatment alone versus the same intra-articular treatment combined with oral micronized /ultramicronized PEA in patients with knee joint degeneration due to osteoarthritis or rheumatoid arthritis.

03

Conditions studied

  • Degenerative Joint Disease of Knee
  • Rheumatoid Arthritis

Keywords

  • Neuroinflammation
  • Palmitoylethanolamide
  • Adelmidrol
  • Hyaluronic Acid
  • Intra-Articular Injection
  • Knee Pain
  • Arthritis, Rheumatoid
  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 40 years
  • Male or female
  • Diagnosis of unilateral or bilateral knee joint degeneration due to osteoarthritis or rheumatoid arthritis, Kellgren-Lawrence grade II-III
  • Duration of knee pain ≥ 6 months
  • Baseline WOMAC score ≥ 20
  • Drug therapy stabilized for at least 3 months in the case of patients with rheumatoid arthritis
  • Naïve to palmitoylethanolamide treatment
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Severe progressive systemic diseases
  • to intra-articular knee injections
  • Intra-articular knee injections within 3 months prior to enrollment
  • Knee surgery within 6 months prior to enrollment
  • Systemic treatment with chondroprotectors within 1 month prior to enrollment
  • Systemic treatment within 1 month prior to enrollment
  • Chronic Non-Steroidal Anti-Inflammatory Drugs (NSAID) therapy
  • Pregnancy or breastfeeding
  • Known to study treatments
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group A (Hyadrol®)

    Participants receive intra-articular injections of adelmidrol 2% / hyaluronic acid 1% (Hyadrol®) administered once weekly for three consecutive weeks.

    Device: Adelmidrol 2% / Hyaluronic Acid 1%

  • Experimental
    Group B (Hyadrol® + m-/um-PEA)

    Participants receive intra-articular injections of adelmidrol 2% / hyaluronic acid 1% (Hyadrol®) administered once weekly for three consecutive weeks, combined with oral micronized/ultramicronized palmitoylethanolamide (m-/um-PEA) (Normast® MPS), one sachet twice daily for 6 weeks, followed by 1 sachet daily for 8 weeks.

    Device: Adelmidrol 2% / Hyaluronic Acid 1% · Dietary Supplement: micronized Palmitoylethanolamide (mPEA) 300mg + ultramicronized Palmitoylethanolamide (umPEA) 600mg

Interventions

  • DeviceAdelmidrol 2% / Hyaluronic Acid 1%

    Ultrasound-guided intra-articular knee injection, 2 mL per injection, administered once weekly for three weeks.

    Also known as: Hyadrol®

  • Dietary supplementmicronized Palmitoylethanolamide (mPEA) 300mg + ultramicronized Palmitoylethanolamide (umPEA) 600mg

    Drug page: PalmidrolStudies of PalmidrolPalmidrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of m-/um-PEA, one sachet twice daily for 6 weeks, followed by 1 sachet daily for 8 weeks.

    Also known as: Normast® MPS

06

What researchers measure

Primary outcomes

  1. Change in joint symptoms and function

    Evaluation of degenerative joint disease symptoms and function assessed by Western Ontario and McMaster Universities (WOMAC) scale, a self-report questionnaire consisting of 24 questions divided in pain (5 items), joint stiffness (2 items) and functional limitations (17 items). Each question has 5 possible answers, evaluated on a Likert scale, from 0 (none) to 4 (extreme): * pain: score from 0 to 20; * joint stiffness: score from 0 to 8; * functional limitations: score from 0 to 68. The sum of the individual scores results in an overall score from 0 to 96 (96 indicates severe disability).

    Time frame: Baseline (T0) and 1 month after treatment (T3)

Secondary outcomes

  1. Change in WOMAC score

    Evaluation of degenerative joint disease symptoms and function assessed by Western Ontario and McMaster Universities (WOMAC) scale, a self-report questionnaire consisting of 24 questions divided in pain (5 items), joint stiffness (2 items) and functional limitations (17 items).

    Time frame: Baseline (T0), 1 week (T1), 2 weeks (T2), 3 months after treatment (T4) and 6 months after treatment (T5)

  2. Change in pain intensity

    Evaluation of pain intensity assessed by the Visual Analogue Scale (VAS) scored from 0 mm to 100 mm, where 0 indicates 'no pain' and 100 corresponds to 'the worst pain ever possible'. The higher the score, the more severe the pain.

    Time frame: Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)

  3. Change in patients' quality of life

    Quality of Life evaluated by the 12-Item Short Form Health Survey (SF-12). The SF-12 is a self-reported health questionnaire. The score produces two summary measures: a mental (MCS-12) and a physical component score (PCS-12). The PCS-12 score is derived from the subdimensions of general health, physical functioning, role physical, and bodily pain, while the MCS-12 score is derived from the subdimensions of social functioning, role emotional, mental health, and energy. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: Baseline (T0), 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)

  4. Incidence of Treatment-Related Adverse Events (Safety and Tolerability)

    Treatment safety is assessed by monitoring the incidence and severity of adverse events immediately after injections and throughout the study.

    Time frame: From first treatment administration up to 6 months after treatment

  5. Change in analgesic consumption

    Analgesic consumption is evaluated by the Cumulative Analgesic Consumption Score (CACS), an index that quantifies the overall use of analgesic medications, taking into account the type, dosage, and frequency of the different analgesics administered.

    Time frame: Baseline (T0), 1 week (T1), 2 weeks (T2), 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)

  6. Change of patients' self-assessed health status

    The patient's global health status is evaluated through the Likert Patient Global Impression of Change (PGIC) scored in 7 points (from 1, very much improved to 7, very much worse).

    Time frame: 1 month after treatment (T3), 3 months after treatment (T4) and 6 months after treatment (T5)

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 12 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 2, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07680101
Collaborators
Azienda Ospedaliera Universitaria Integrata Verona
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Enrico Polati
Contact
enrico.polati@aovr.veneto.it
+39 045 812 6076
Enrico Polati
principal investigator · Università di Verona, Dipartimento di Scienze Chirurgiche Odontostomatologiche e Materno-Infantili

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palmidrol

Start the discussion